Among those with T-ALL, patients with a CDKN2A deletion revealed significantly reduced CDKN2A expression compared with those without a deletion (0.258; 0.048–3.176 vs. 41.288; 1.912–238.943, P < 0.001; Fig. 3a, c). Here, CDKN2A is linked to acute lymphoblastic leukemia.